Efficacy of an autophagy-targeted DNA vaccine against avian leukosis virus subgroup J

详细信息    查看全文

• 作者：Zhenkai Dai^a ; ^b ; Jianfei Huang^a ; ^b ; Xiaoya Lei^a ; ^b ; Yiming Yan^a ; ^b ; Piaopiao Lu^a ; ^b ; Huanmin Zhang^c ; Wencheng Lin^a ; ^b ; ^d ; Weiguo Chen^a ; ^b ; ^d ; Jingyun Ma^a ; ^b ; Qingmei Xie^a ; ^b ; ^d ; ^{qmx@scau.edu.cn}
• 关键词：DNA vaccine ; Avian leucosis virus ; Autophagy ; Rapamycin
• 刊名：Vaccine
• 出版年：2017
• 出版时间：1 February 2017
• 年：2017
• 卷：35
• 期：5
• 页码：808-813
• 全文大小：550 K
• 卷排序：35

文摘

Infection with the avian leukosis virus subgroup J (ALV-J) can lead to neoplastic disease in chickens, inflicting significant economic losses to the poultry industry. Recent reports have identified inhibitory effects of ALV-J on autophagy, a process involving in innate and adaptive immunity. Inspired by this connection between autophagy and immunity, we developed a novel DNA vaccine against ALV-J which includes co-administration of rapamycin to stimulate autophagy. To measure the efficacy of the developed prototype vaccine, five experimental groups of seven-day-old chickens was immunized three times at three-week intervals respectively with vector, pVAX1-gp85, pVAX1-gp85-LC3, pVAX1-gp85 + rapamycin and pVAX1-gp85-LC3 + rapamycin through electroporation. We then tested their antibody titers, cytokine levels and cellular immune responses. The immunoprotective efficacy of the prototype vaccines against the challenge of the ALV-J GD1109 strain was also examined. The results showed that the combination of pVAX1-gp85-LC3 and rapamycin was able to induce the highest antibody titers, and enhance interleukin(IL)-2, IL-10 and interferon (IFN)-γ expression, and the chickens immunized with the combination of pVAX1-gp85-LC3 and rapamycin showed the highest percentage of CD3+ CD8+ T lymphocytes. Based on our results, we suggest that stimulating autophagy can improve the efficacy of DNA vaccines and that our DNA vaccine shows the potential of being a candidate vaccine against ALV-J. This study provides a novel strategy for developing vaccines against ALV-J.